 |
|
|
 |
|
Raising Capital At-The-Market: a Prescription for a Solid Long-Term Financing Strategy
Date: May 11, 2011
Client: Brinson Patrick
Summary: Companies in emerging industries such as the life sciences are constantly looking for funding, but uncertainty in the capital markets has made this a time-sensitive, challenging and expensive process to execute.
|
|
|
|
 |
|
San Diego’s Polaris Moves to Late-Stage Test of Drug for Liver Cancer and Other “Arginine-Dependant” Tumors
Date: April 27, 2011
Client: Polaris Group
Summary: Bor-Wen Wu says he had the North Star in mind in 2006 when he founded San Diego’s Polaris Group, a small holding company with a promising lead drug candidate for treating liver cancer, malignant melanoma, and other related cancers. As an explorer in science, Wu says, “I need a North Star to tell me where to go.”
|
|
|
|
 |
|
AVI BioPharma to Present Company Overview at the Deutsche Bank 36th Annual Health Care Conference
Date: April 26, 2011
Client: AVI BioPharma
Summary: AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the Deutsche Bank 36th Annual Health Care Conference in Boston on Monday, May 2, at 8:40 a.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.
|
|
|
|
 |
|
Endocyte Announces Intent to Seek Conditional Marketing Authorization in the European Union for Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 for Platinum-Resistant Ovarian Cancer
Date: April 26, 2011
Client: Endocyte, Inc.
Summary: WEST LAFAYETTE, Ind., April 26, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced its plan to prepare two marketing authorization applications to the European Medicines Agency (EMA). These two marketing applications are for the company's lead drug candidate EC145 for the treatment of platinum-resistant ovarian cancer and its companion imaging diagnostic EC20 for patient selection. The filings will be based on the results of the randomized Phase 2 PRECEDENT trial and supported by a Phase 2 single agent EC145 clinical trial.
|
|
|
|
 |
|
AGA Digestive Health Outcomes Registry™, Powered by MedAssurant Healthcare Data Analytics, Announces New Research Partner
Date: April 26, 2011
Client: MedAssurant, Inc.
Summary: BOWIE, Md. – April 26, 2011 – MedAssurant, Inc., and the American Gastroenterological Association (AGA) today announced that Vertex Pharmaceuticals will utilize the AGA Digestive Health Outcomes RegistryTM to perform unique data analysis projects. Powered by MedAssurant’s advanced healthcare data analytics, the AGA Registry is the largest of its kind in the field of gastroenterology – focused initially on guidelines-driven management of inflammatory bowel disease (IBD) and effective strategies for colorectal cancer (CRC) prevention, as well as hepatitis C.
|
|
|
|
 |
|
ACT's Chief Scientific Officer Robert Lanza, M.D., to Deliver Speech at 3rd International Collaborative Symposium on Stem Cell Research in Seoul, South Korea
Date: April 26, 2011
Client: Advanced Cell Technology
Summary: MARLBOROUGH, Mass., April 26, 2011 /PRNewswire/ -- Advanced Cell Technology ("ACT"; OTCBB:ACTC), a leader in the regenerative medicine space, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a keynote lecture at the 3rd International Collaborative Symposium on Stem Cell Research, April 29-30, in Seoul, South Korea. Dr. Lanza's presentation, "The First Human Embryonic Stem Cell Trials," will be delivered on Friday, April 29, and will feature ACT's two upcoming human clinical trials using human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) to treat forms of macular degeneration, and related topics.
|
|
|
|
 |
|
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
Date: April 18, 2011
Client: Amarin Corporation plc
Summary: MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
|
|
|
|
 |
|
Parkinson's Update: Disease Pipeline Running the Gamut
Date: April 11, 2011
Client: Cynapsus Therapeutics, Inc.
Summary: There were roughly 40 million Americans over the age of 65 in 2010, but as the baby boomer generation continues to reach the monumental age, the number of Americans in that class is expected to increase to 70 million in 2030.
|
|
|
|
 |
|
MorphoSys Initiates Infectious Disease Alliance with ContraFect
Date: April 11, 2011
Client: MorphoSys AG
Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today the formation of a new alliance with US-based biotechnology company ContraFect Corp. in the discovery and development of therapeutic antibodies for infectious diseases. Under the terms of the five-year agreement, ContraFect will receive access to HuCAL PLATINUM, the latest and most powerful version of MorphoSys's antibody libraries, and AutoCAL at its facility in New York. Payments under the agreement include committed annual license fees in addition to success-based development milestones. MorphoSys also stands to receive royalties on sales of marketed drug products emerging from the collaboration.
|
|
|
|
 |
|
Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells
Date: April 7, 2011
Client: Cellular Dynamics International, Inc.
Summary: MADISON, WIS., April 7, 2011 – Cellular Dynamics International, Inc. (CDI), the world's only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led by an entity affiliated with Tactics II Stem Cell Ventures, which along with its affiliates led CDI's prior capital raises. Other investors in this financing round include Sam Zell's Equity Group Investments LLC, Sixth Floor Investors LP and G Force Investments LLC. CDI has raised a total of $100 million since 2004.
|
|
|
|
 |
|
Zacharon Pharmaceuticals Announces Research and Development Collaboration with Pfizer to Develop Drugs for Multiple Rare Disorders
Date: April 7, 2011
Client: Zacharon Pharmaceuticals, Inc.
Summary: SAN DIEGO, April 7, 2011 – Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon’s innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans
|
|
|
|
|
|
AVI BioPharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock
Date: April 6, 2011
Client: AVI BioPharma, Inc.
Summary: AVI BioPharma, Inc. (NASDAQ: AVII) today announced that, in connection with its previously announced public offering, the underwriters have exercised in full their over-allotment option to purchase an additional 3,000,000 shares of AVI BioPharma's common stock at $1.50 per share, less underwriting discounts and commissions. AVI BioPharma also announced that it has closed its public offering of 23,000,000 shares of common stock at a public offering price of $1.50 per share, which included the sale of the shares pursuant to the over-allotment option. After deducting underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $32.0 million.
|
|
|
|
 |
|
Pfizer, Biotech Partner to Develop Drugs for Rare Diseases
Date: April 6, 2011
Client: Zacharon Pharmaceuticals Inc.
Summary: Pfizer Inc. is teaming up with a biotechnology firm in an unusual early-stage drug-development deal that could be worth as much as $210 million and bolster the drug giant's new push into rare diseases.
|
|
